Clinical trial
Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab
NCT00259740 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00259740 |
|---|---|
| Title | Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab |
| Official title | An Open-Label, Multi-Center Phase 2 Trial of Denosumab in the Treatment of Relapsed or Plateau-Phase Multiple Myeloma |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Relapsed or Plateau-Phase Multiple Myeloma |
| Intervention type | Drug |
| Interventions | DENOSUMAB |
| Enrollment | 96 |
| Start date | Nov 1, 2005 |
| Primary completion | Aug 1, 2007 |
| Completion | Dec 1, 2011 |
| First posted | Dec 1, 2005 |
| Last update posted | Mar 15, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: